Dry Powder Inhalation of Nintedanib in Dibasic Calcium Phosphate for Targeting the Lungs in Pulmonary Fibrosis
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Sanjay Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: CSIR-Central Drug Research Institute, Lucknow 226031, India. Hauptthemen laut MEDLINE: Indoles, Pulmonary Fibrosis, Calcium Phosphates, Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Central Drug Research Institute.
Abstract (Originalsprache)
We prepared three variants of nintedanib dry powder inhalations (DPIs), one with dibasic calcium phosphate dihydrate (CaHPO4·2H2O) and two with lactose monohydrate as the carrier. CaHPO4 is not reported as a DPI excipient. We compared nintedanib pharmacokinetics and efficacy of the CaHPO4 formulation against bleomycin-induced pulmonary fibrosis following oral (3.875 mg/q12h) and DPI (200 μg/12 h) dosing in rats. Blood plasma Cmax, Tmax, and AUC resulting from oral dosing and DPI were 780 versus 147.5 μg/mL, 2.47 versus 2.22 h, and 5562 versus 1094 μg/mL·h, respectively. Drug remaining in the lungs and airways at the end of 12 h of dosing with the DPI (2.41 ± 0.37 μg/g of tissue) was double the amount found after oral dosing (1.25 ± 0.56 μg/g). Lung fibrosis induced in rats using bleomycin was resolved equally well by the two interventions administered q12h for 14 days. We submit that the reduction in systemic exposure to nintedanib and enhanced exposure to target tissue could offer significant therapeutic and safety advantages, and CaHPO4 can be easily developed as an excipient for DPIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CSIR-Central Drug Research Institute, Lucknow 226031, India.
- Jawaharlal Nehru University (JNU), New Delhi 110067, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
ORCID-Profile: Himanshu Bansode, Amit Misra
Förderung
- Council of Scientific and Industrial Research, India
- Central Drug Research Institute
Zitieren
APA
Singh, S., Francis, F., Barsain, M., Kothuri, N., Verma, S., Bansode, H., J V U S, C., Yadav, C., Sharma, A. K., Moharana, B., Panda, G., & Misra, A. (2025). Dry Powder Inhalation of Nintedanib in Dibasic Calcium Phosphate for Targeting the Lungs in Pulmonary Fibrosis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01190
Vancouver
Singh S, Francis F, Barsain M, Kothuri N, Verma S, Bansode H, et al. Dry Powder Inhalation of Nintedanib in Dibasic Calcium Phosphate for Targeting the Lungs in Pulmonary Fibrosis. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01190
BibTeX
@article{Singh2025,
author = {Singh, Sanjay and Francis, Frinto and Barsain, Mohit and Kothuri, Naresh and Verma, Sonia and Bansode, Himanshu and J V U S, Chakradhar and Yadav, Chunna and Sharma, Ashok Kumar and Moharana, Baisakhi and Panda, Gautam and Misra, Amit},
title = {Dry Powder Inhalation of Nintedanib in Dibasic Calcium Phosphate for Targeting the Lungs in Pulmonary Fibrosis},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01190}
}
EUVIMED